Guide lines for Treating Eating Disorder
-
Upload
heba-essawy -
Category
Health & Medicine
-
view
132 -
download
1
description
Transcript of Guide lines for Treating Eating Disorder
![Page 1: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/1.jpg)
GUIDELINES FOR THE PHARMACOLOGICAL TREATMENT
OF EATING DISORDERS By Heba Essawy
Prof Of Psychiatry
![Page 2: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/2.jpg)
EATING DISORDERS Eating disorders including: •Anorexia nervosa.(AN) •Bulimia nervosa. (BN) •Eating disorder not otherwise specified Binge eating disorder.(BED) Night eating syndrome.(NED) * Obesity.
![Page 3: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/3.jpg)
COMORBIDITY IN EATING DISORDERS Affective and anxiety disorders . Obsessive compulsive disorders,
impulse control disorders . Psychosis . Substance use disorders. Pain Disorder.
![Page 4: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/4.jpg)
EATING DISORDER: TREATMENT
Complex process -Psychotropic drugs -Psychotherapy -Nutritional counseling, -Treatment of medical complications.
![Page 5: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/5.jpg)
MANAGEMENT OF ED
A .Coordinating Care and Collaborating with Other Clinicians.B .Assessing and Monitoring Eating Disorder Symptoms and Behaviors.c. Assessing and Monitoring the Patient's General Medical Condition.d. Assessing and Monitoring the Patient's Safety and Psychiatric Status.E-Providing Family Assessment and Treatment
![Page 6: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/6.jpg)
SELECTION OF TREATMENT SITE
1.Outpatient 2.Partial hospitalization (full-day outpatient care) 3.Residential treatment center 4.Inpatient hospitalization
![Page 7: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/7.jpg)
HOSPITALIZATION IN ANBefore the onset of medical instability. Abnormalities in vital signs -Marked orthostatic hypotension -Increase in pulse of 20 bpm. -Drop in standing bl pr. 20mmHg.
-Bradycardia <40 bpm. -Tachycardia >110 bpm. - Hypothermia.
![Page 8: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/8.jpg)
HOSPITALIZATION IN BN Serious concurrent medical problems -Metabolic abnormalities. - Hematemesis. - Uncontrolled vomiting Serious psychiatric disturbances - Suicidality. - Other psychiatric diagnosis. - Severe alcohol or drug dependence .
![Page 9: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/9.jpg)
AIM OF TREATMENTS FOR AN 1) Restore patients to a healthy weight: * with the return of menses *normal ovulation in female patients. * normal sexual drive and hormone levels in male . * normal physical and sexual growth in children. 2) Treat physical complications. 3) Enhance motivation to enhance healthy Eating patterns . 4) Education for healthy Nutrition and Eating patterns.
![Page 10: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/10.jpg)
AIM OF TREATMENTS FOR AN 5) Change core dysfunctional cognitions, attitudes, motives, conflicts. 6) Treat associated psychiatric conditions, mood and impulse and self-esteem and behavioral problems 7) Provide family counseling. 8) Prevent Relapse.
![Page 11: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/11.jpg)
TREATMENT WITH ANTIDEPRESSANTS
The rationale for treating AN (1) Dysfunction in the serotonergic and noradrenergic system in the pathophysiology (2) Comorbidity with * Anxiety disorders. *Obsessive compulsive *Depression.
![Page 12: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/12.jpg)
TRICYCLICS - Clomipramine: increased hunger,
appetite and energy intake, but no weight gain.
(Lacey and Crisp (1980) ) - Amitriptyline : No significant weight gain. (Biederman et al. (1985))
No clear evidence for the general use of tricyclic in AN except for depression.
![Page 13: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/13.jpg)
SSRIS : CITALOPRAM
Open randomized study of Fassino(2002) No differences in BMI or weight gain . Improvement in : - Depression. - Obsessive-compulsive symptoms. - Impulsiveness -Trait-anger in AN-R type.
![Page 14: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/14.jpg)
FLUOXETINE Gwirtsman et al.(1990) : diminished
depressive symptoms was associated with weight gain.
Kaye et al. (2001): patients on fluoxetine(1 year): reducion in relapse rate
increase weight and reduction of symptoms. Walsh et al.(2006a) : No benefit from
fluoxetine in reducing relapse rate AN but ttt obsessive symptoms.
![Page 15: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/15.jpg)
SERTRALINE. Effectiveness for sertraline
regarding - Depressive symptoms - Not concerning weight gain
(Santonastaso et al., 2001)
![Page 16: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/16.jpg)
MIRTAZAPINE Efficacious with long-standing AN . After 9-month follow-up :
- weight gain. - improve mood.
Mirtazapine: for older, chronically ill patients comorbid depression.
( Safer et al. (2010) )
![Page 17: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/17.jpg)
DISCUSSION: ANTIDEPRESSANTS
Antidepressants : may be used in AN -with depressive symptomatology - with comorbid obsessive disorder - Not in general.
![Page 18: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/18.jpg)
ANTIPSYCHOTICS:HALOPERIDOL
Cassano et al. (2003) report an opentrial with haloperidol AN-R over 6 month.
Haloperidol - might be effective as adjunct treatment for AN-R ( severe cases) .
![Page 19: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/19.jpg)
ANTIPSYCHOTICS SULPIRIDE : - No statistical sig. over placebo .
PIMOZIDE: - Induce weight gain ?.
Vandereycken (1984)
![Page 20: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/20.jpg)
ATYPICAL ANTIPSYCHOTICS:OLANZAPINE Promising weight gain &
psychopathological improvement in AN (Barbarich et al., 2004)
Reduced anorexic ruminations but no difference in BMI (Mondraty et al. (2005).
Superior for rate of weight gain, Early achievement of target BMI Early in reduction of obsessive (Bissada
et al. (2008). Olanzapine** seems to be a promising inAN–BP type.
![Page 21: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/21.jpg)
ATYPICAL ANTIPSYCHOTICS RISPERIDONE* may be useful in AN .
(Newman-Toker, 2000)
QUETIAPINE* :Low-dose (100-400mg) resulted in both psychological and physical improvements, with minimal side-effects.
( Court et al. (2010))
![Page 22: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/22.jpg)
ATYPICAL ANTIPSYCHOTICS AMISULPRIDE : promising results with
combination with fluoxetine.
(Ruggiero et al. (2001)
ARIPIPRAZOLE : need longer period time
(Trunke et al. (2010)
![Page 23: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/23.jpg)
ANTIHISTAMINICS Cyproheptadine: Effective in severely ill AN patient in
weight gain.
Increased weight gain in non-bulimic group and impaired treatment in bulimic group.
(Bartra et al., 2006).
![Page 24: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/24.jpg)
TREATMENT WITH OTHER PHARMACOLOGICAL COMPOUNDS Zinc** : in Adolescent with AN at risk
for zinc deficiency , good respond after zinc supplementation (50 mg elemental zinc/day).
( Safai-Kutti (1990)
Oral administration of 14 mg of elemental
zinc daily for 2 months in AN is routine.
(Birmingham (2006))
![Page 25: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/25.jpg)
TREATMENT WITH OTHER PHARMACOLOGICAL COMPOUNDS Lithium : -One RCT found no efficacy for Lithium over placebo. -One RCT found efficacy over placebo concerning binges or purges. (Gross et al. (1981)
-Cisapride: concerning gastric emptying are conflicting. Whereas one study found no
efficacy over placebo, 1 study found a difference for gastric emptying. (Category
grade E evidence).
![Page 26: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/26.jpg)
TREATMENT : NALTREXONE Naltrexone : - Auto-addiction model for AN and BN - 100 mg naltrexone twice a day with for 6 weeks . - Decrease Binge and Purging behaviour AN and BN. -No weight restoration in AN in week 6.
(Marrazzi et al. (1995))
![Page 27: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/27.jpg)
GROWTH HORMONE recombinant human growth hormone (rhGH) :
No weight gain between pharmacological group and placebo group
( Hill et al. (2000)
![Page 28: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/28.jpg)
NASOGASTRIC TUBE FEEDING
Weight gain was 39% higher in the tubegroup than in the control group.
After discharge the relapse free period was longer in the tube group.
( Rigaud et al. (2007) .
![Page 29: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/29.jpg)
COMBINING PHARMACOTHERAPY WITH PSYCHOTHERAPY No clear evidence to recommend the
addition of pharmacotherapy to psychotherapy in AN with comorbidities
- depression. -obsessions. - compulsions. - anxiety.
![Page 30: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/30.jpg)
BULIMIA NERVOSA : TRICYCLIC AD
Imipramine: reduce bulimic behaviour .
Amitryptiline :with no clear evidence of superiority only in the depressive subgroup.
Desipramine: reduce bulimic
behaviour.
![Page 31: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/31.jpg)
SSRIS Citalopram : no clear efficacy in
bulimia nervosa over placebo Fluoxetine***: showing an efficacy
over placebo concerning bulimic behaviour.
Fluvoxamine** 3 RCTs with 2 showingefficacy over placebo concerning bulimic behaviour Sertraline **: one RCT that showsefficacy over placebo concerning bulimic behaviour
![Page 32: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/32.jpg)
MAOI Moclobemide shows no efficacy in BN in 1 RCT .
Phenelzine shows an efficacy concerning bulimic behaviour ( Cheese reaction ) ( Not recommended )
![Page 33: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/33.jpg)
ANTIDEPRANSANT – MOOD STABILIZERS No RCT, no evidence for -Duloxetine. -Bupropion - Lithium - Trazodone - Mianserin -Carbamazepine - Oxcarbamazepine
![Page 34: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/34.jpg)
ANTIEPILEPTIC, LIGHT THERAPY Topiramate*** with efficacy in reducing
BN associated psychopathology behaviour. for topiramate in BN, with a moderate risk-benefit ratio.
Naltrexone Inconsistent results
Methylphenidate Inconsistent results
Light therapy in reducing psychopathology in BN.
![Page 35: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/35.jpg)
PHARMACOTHERAPY IN BN Available literature on pharmacological
treatment of BN is based on trials of relatively short duration( less 6 months)
No enough information on the long-term efficacy of these treatments.
![Page 36: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/36.jpg)
BINGE EATING DISORDER (BED) Antidepressants ; 3 RCTs 2 with
imipramine*** 1 with Desipramine showing a reduction in binge frequency.
Citalopram/escitalopram***: 2 RCTs showing
efficacy in BED over placebo .
Fluvoxamine: 3 studies with no favourable results .
![Page 37: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/37.jpg)
BINGE EATING DISORDER (BED): TREATMENT Fluoxetine: there are conflicting resultsconcerning efficacy in BED.
Sertraline*** Effective in 2 RCTs over placebo concerning psychopathology and BE.
Atomoxitine** : one RCT that shows efficacy in BED .
Venlafaxine : One RCT suggests that there might be efficacy in BED.
![Page 38: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/38.jpg)
BINGE EATING DISORDER (BED): TREATMENT
Venlafaxine**:effective over placebo. Sibutramine ***: over placebo in BED
but low risk-benefit ratio. Reboxetine *:in BED . Topiramate ***: 3 RCTs that suggest
efficacy over placebo in BED with moderate risk-benefit ratio.
![Page 39: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/39.jpg)
BINGE EATING DISORDER (BED): TREATMENT Zonisamide ** efficacy in
psychopathology, weight and BED behaviour.
Baclofen* : may be helpful in reducing frequency of binge eating.
Orlistat *** : effective in 3 RCTs over placebo in reducing weight in BED with low to moderate risk -benefit ratio.
d-fenfluramin **: efficacy over placebo for in reducing binges per week in BED
Naltroxone **: efficacy over placebo inreducing binge duration in BED .
![Page 40: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/40.jpg)
BINGE EATING DISORDER (BED): CONCLUSION The available literature on
pharmacological treatment of BED is based on trials
of relatively short duration ( less than 6 months ) No enough information on the long-term
efficacy of these treatments.
![Page 41: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/41.jpg)
NUTRITIONAL REHABILITATION
1.Establishment of healthy target weights 2.Nutritional rehabilitation and refeeding programs 3.Establishment of expected rates of controlled weight
gain 4.Setting advancing intake levels 5.Vitamin and mineral supplementation (e.g.,
phosphorous) 6.Monitoring of serum potassium and rehydration 7.Setting physical activity 8.Other treatments, when indicated, including liquid
food supplements; nasogastric feedings; parenteral feedings
9.Monitoring and treatment of symptoms and conditions associated with gaining weight (e.g., anxiety, abdominal pain, constipation)
![Page 42: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/42.jpg)
PSYCHOSOCIAL INTERVENTIONS IN AN
1.Family psychotherapy for children and adolescents
2.Family group psychoeducation for adolescents 3.Cognitive-behavioral therapy (CBT) for adults 4.Interpersonal therapy (IPT) and/or
psychodynamically oriented individual or group psychotherapy for adults
5.Psychosocial interventions based on addiction models
6.Support groups led by professionals . 7.Internet-based support . 8.Non-verbal therapeutic methods (e.g., creative
arts, movement therapy, occupational therapy)
![Page 43: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/43.jpg)
PSYCHOSOCIAL INTERVENTIONS 1) Understand and cooperate with their
nutritional and physical rehabilitation. 2) understand and change the
behaviors and dysfunctional attitudes related to their eating disorder.
3) improve their interpersonal and social functioning.
4) address comorbid psychopathology and psychological conflicts that reinforce or maintain eating disorder behaviors.
![Page 44: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/44.jpg)
Anorexia Bulimia
Ch.byDisturbed body image Binge eating
Weight loss 85% of expected.
Wt loss 15%
Specify typeRestricting Purging
Binge/Purging Non purging
Life time prevailing in female
0.5-3.7% 1-4%
Age of onset 10-30ys 16-18ys
M:F 1: 10 1:5
Biological etiology
MHPG in urine a CST NE
endorphins 5-HT
endorphins
Course
40% recovery relapse in 50% in system
30% improve
30% chance
![Page 45: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/45.jpg)
Anorexia Bulimia
Treatment Hospitalization Hospitalization
Weight Metabolic alkalosis
Metabolic balance
Pharmacotherapy FluoxetineMirtazapine
Fluxetine Fluvoxamine-sertraline
Olanazapine, resperidone -quetiepine
Topiramate
cyproheptadine -
Elemental zinc -
Psychological Group therapy Individual therapy
Cognitive Cognitive
Family therapy Group therapy.
![Page 46: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/46.jpg)
TREATMENT IN BED Antideprasant Imipramine. Citalopram- ecitalopram. Sertraline. Mood stabilizer Topiramate Atomoxitine. Sibutramine.
![Page 47: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/47.jpg)
Thank s a lot
![Page 48: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/48.jpg)
DRUG
Antideprasants: Fluxetine
Mirtazapine
Antipsychotics olanzapine
Resperidone
Quetiapen
Antihistaminic Cyproheptadine
supplements Zinc
![Page 49: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/49.jpg)
![Page 50: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/50.jpg)
![Page 51: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/51.jpg)
![Page 52: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/52.jpg)
![Page 53: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/53.jpg)
![Page 54: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/54.jpg)
![Page 55: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/55.jpg)
![Page 56: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/56.jpg)
![Page 57: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/57.jpg)
![Page 58: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/58.jpg)
![Page 59: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/59.jpg)
![Page 60: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/60.jpg)
![Page 61: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/61.jpg)
![Page 62: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/62.jpg)
![Page 63: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/63.jpg)
![Page 64: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/64.jpg)
![Page 65: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/65.jpg)
![Page 66: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/66.jpg)
![Page 67: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/67.jpg)
![Page 68: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/68.jpg)
![Page 69: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/69.jpg)
![Page 70: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/70.jpg)
![Page 71: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/71.jpg)
![Page 72: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/72.jpg)
![Page 73: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/73.jpg)
![Page 74: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/74.jpg)
![Page 75: Guide lines for Treating Eating Disorder](https://reader034.fdocuments.net/reader034/viewer/2022052619/555d9212d8b42a6c3d8b59b6/html5/thumbnails/75.jpg)